Market Analysis, Clin Dermatol Res J Vol: 4 Issue: 3
Aging can be fun if you lay back and enjoy it
Director Education & Clinical, Asia-Pacific Centre for Neuromodulation, Australia, E-mail: email@example.com
World Aging Meet 2020 welcomes attendees, presenters, and exhibitors from all over the world to Bali. We are delighted to invite you all to attend and register for the “2nd International Conference on Aging” which is going to be held during June 22-23, 2020 in Abu Dhabi, UAE.
The organizing committee is set up for a thrilling and exciting conference program including complete lectures, workshops on a variety of topics, symposia, poster presentations and various programs for participants from all over the world. We invite you to join us at the World Aging Meet 2020, where you will be sure to have a meaningful experience with scholars from around the world. All members of the World Aging Meet 2020 organizing committee look forward to meeting you in Bali.
Market Analysis for World Aging Meet 2020
Importance & Scope:
‘Aging Meet 2020” is a perfect platform to present and discuss current perspectives in drug research and development. Pharmacology is the study of interaction of chemical with living systems. It is a medical science that forms a backbone of the medical profession. So, it’s important to describe the pharmacological basis of therapeutics in order to maximize the benefits and minimize the risks of drugs to recipients. It is an integrative rather than an autonomous science, drawing on the techniques and knowledge of many allied scientific disciplines. Hence it will be a platform for researchers, scientists, professional involved with drug development.
Market Analysis of Aging and Related Research
Healthcare CRO Market to Reach $45.2 Billion By 2022
Global Healthcare CRO industry is expected to reach USD 45.2 billion by 2022, according to a new report by Grand View Research Inc. With the increasing number of patents expiring, increasing number of partnerships to identify biologics and new compounds and growing R&D costs, drug maker and sponsor companies are under pressure to replace the revenue loss specifically due to generics, which has further made drug development more expensive and complex.
Moreover, owing to the increasing incidence rates of chronic diseases such as cancer, Alzheimer’s and other infectious diseases in children, government funding has increased, which have led to increasing R&D activities.
Global pharmacovigilance market, by clinical trials, 2012 – 2020 (USD Million)
Increasing incidence rates of ADR (adverse drug reaction) clubbed with the introduction of stringent government policies pertaining to drug safety regulations are some key factors expected to drive the pharmacovigilance market. Pharmacovigilance is referred as an act of collection, detection, reporting and monitoring of adverse drug reaction. The global pharmacovigilance market was valued at USD 2,408.0 million in 2013 and is expected to grow at a CAGR of 12.6% during the forecast period. ADR represents a substantial burden on healthcare systems and is one of the prominent reasons of morbidity in developed countries. Approximately 5% of total hospitalizations in a year are due to ADR which makes reporting and preventing of the same a notable growth fuelling factor for this market. Growing prevalence of chronic disorders coupled with rising geriatric population base has heightened the need for new drug development. With an upsurge in the drug production, regulatory authorities such as the U.S. FDA and EMEA (European Medicines Agency) have intensified drug safety regulations prior and post commercialization. Growing complexity of drug safety regulations is thus, expected to boost market growth during the forecast period. Additionally, there is an additional pressure from the regulators for electronic submission especially in European countries which would further accentuate the demand for this market in this region.
Worldwide Total Pharmaceutical R & D spend in 2006 - 2020
We are unaware of exact validated statistics which accurately estimate the volume of clinical trial logistics services. Thus, such volume is traditionally calculated as a percentage of the total clinical trials expenses. According to the forecast made by Evaluate Pharma, in the next 5 years the clinical trials market will show a stable low growth of 2-2.5% per year, while being accompanied by a significant paradigm shift in the operational structure of cold-chain logistics and clinical trial supply, the costs of which (including manufacturing), by various estimates, may reach up to 20% of the total R&D costs.
According to the same report, this trend of disproportionate growth will come from an increase in clinical trials of prescription medications where logistical expenses are traditionally higher than those of trials of generic products.
Also noteworthy is the prediction that by 2020 R&D projects of top-20 pharmaceutical companies will account for more than 60% of total clinical trial expenses.
Cardiovascular Surgical Devices: Technologies and Global Markets
The global market for cardiovascular surgical devices was valued at $29.7 billion in 2012. This market is expected to reach nearly $31.7 billion in 2013 and nearly $47.2 billion by 2018, a compound annual growth rate (CAGR) of 8.3% for the period of 2013 to 2018.
BCC analyses the industry on a worldwide basis from market, product and technology perspectives. Regulations and reimbursement issues and patents issued from 2010 through mid-2013 are also examined to identify patient safety, regulatory review and insurance coverage issues for stakeholders and potential stakeholders in this industry.
Blood-Brain Barrier Technologies and Global Markets
The global market for blood-brain barrier (BBB) technology for therapeutics reached $21.8 million in 2013. This market is expected to grow from $38.7 million in 2014 to $471.5 million in 2019, a compound annual growth rate (CAGR) of 64.9% from 2014 through 2019.
Pharmacology Research and Development Forecast
Pharmaceutical industry is experiencing a rather drastic redistribution of R&D activities to new geographic regions. According to the Biopharma Cold Chain 2012 Sourcebook, in 2016 up to 65% of growth in clinical research will come from studies conducted in emerging market counties: Asia Pacific, Eastern Europe and South America. While the majority of clinical trials are initiated with the end goal of NDA approval in the US and in Western Europe, the vast majority of potential study subjects live outside of these regions. Thus, there is a clearly identifiable need to develop first-rate, cost-effective clinical trial infrastructure capabilities in Asia-Pacific region, Latin America, Eastern Europe and potentially in North and South Africa. BRICS countries have demonstrated willingness to make their patients more available to international clinical trials. For instance, Russia and China have recently taken steps towards simplifying the launch of clinical trials.